Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | LOTIS-9: Lonca-T + rituximab in previously untreated unfit and frail patients with DLBCL

Jason Westin, MD, FACP, University of Texas MD Anderson Center, Houston, TX, talks on the rationale and design of the LOTIS-9 study, a Phase II study assessing the efficacy and tolerability of the combination of loncastuximab tesirine (Lonca-T) and rituximab in unfit and frail patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) (NCT05144009). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.